Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.
The FDA approval of Alkermes' new antipsychotic drug Lybalvi couldn't have gone any better for the company, but it could still face a big challenge positioning the new drug in the highly ge
Alkermes and Biogen have filed a new multiple sclerosis pill with the FDA, which they hope will treat the disease with fewer unpleasant gastrointestinal side effects than the big pharma’s o
Alkermes is planning to head to the FDA next year with a new schizophrenia drug that, according to phase III data, could sidestep one of the main side effects of other drugs.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh